BriaCell Therapeutics Raises $13.8 Million in Public Offering to Advance Cancer Immunotherapy Research
BriaCell Therapeutics has completed a public offering of 3,066,666 units, generating approximately $13.8 million to support its clinical-stage cancer immunotherapy development efforts. The funding will help the company advance its research and corporate objectives.
BriaCell Therapeutics, a clinical-stage biotechnology company, has successfully priced a public offering of 3,066,666 units at $4.50 per unit, generating gross proceeds of approximately $13.8 million. The offering, led by ThinkEquity, is scheduled to close on April 28, 2025, subject to customary closing conditions.
Each unit in the offering comprises one common share or pre-funded warrant and one warrant exercisable at $5.25 per share. The company intends to use the net proceeds for working capital, corporate purposes, and advancing its business objectives in cancer immunotherapy research.
The funding represents a significant milestone for BriaCell, providing financial resources to continue developing novel immunotherapies aimed at transforming cancer treatment. By securing this capital, the company can potentially accelerate its research and development efforts, bringing potentially innovative cancer treatment strategies closer to clinical implementation.
The public offering underscores investor confidence in BriaCell's scientific approach and potential to make meaningful contributions to cancer treatment. The funds will enable the company to continue its work in developing cutting-edge immunotherapies that could offer new hope for cancer patients.